ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1162

Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1147

Evaluation of Adverse Pregnancy Outcomes in Patients with Inflammatory Myopathies and Ro Positivity

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1027

Evaluation of Health Disparities in Outcomes of Patients with Juvenile Idiopathic Arthritis

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1081

Evaluation of Methods for Ascertainment and Categorization of Race and Ethnicity for Clinical Research: An Umbrella Review

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 1422

Evaluation of Salivary Gland Focus Score in Sjogren’s Disease Using Deep Learning: A Step Towards Tissue Biomarker Discovery

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1377

Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1341

Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1414

Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1290

Examining the Quality of Surveys Used in Rheumatology Health Professions Education Research

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1176

Exploration of Heterogeneity of Treatment Effects Across Exercise-Based Interventions for Knee Osteoarthritis

Orthopedics, Low Back Pain, & Rehabilitation – ACR/ARP Poster

10:30AM-12:30PM: Abstract Number: 1231

Exploring Long-term Complications of Lyme Disease – Insights from a Retrospective Cohort Study

Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1096

Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1579

Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1374

Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1023

Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors

Healthcare Disparities in Rheumatology Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].